Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Average PT from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has been assigned an average rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $3.9375.

A number of analysts have issued reports on the stock. Ascendiant Capital Markets lifted their price target on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research note on Thursday, November 13th. Finally, Wall Street Zen upgraded shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday.

Lucid Diagnostics Price Performance

Lucid Diagnostics stock opened at $1.45 on Friday. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.80. The firm’s 50 day moving average price is $1.23 and its 200-day moving average price is $1.16. The stock has a market cap of $199.64 million, a P/E ratio of -1.39 and a beta of 1.18.

Institutional Investors Weigh In On Lucid Diagnostics

Several institutional investors have recently modified their holdings of LUCD. Vanguard Group Inc. increased its position in shares of Lucid Diagnostics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock valued at $4,569,000 after purchasing an additional 396,719 shares during the last quarter. Masters Capital Management LLC increased its position in Lucid Diagnostics by 46.6% during the third quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock valued at $4,039,000 after acquiring an additional 1,272,000 shares during the last quarter. Aberdeen Group plc raised its stake in shares of Lucid Diagnostics by 38.3% in the fourth quarter. Aberdeen Group plc now owns 3,457,894 shares of the company’s stock valued at $3,769,000 after acquiring an additional 957,894 shares during the period. Two Seas Capital LP purchased a new stake in Lucid Diagnostics in the 3rd quarter worth about $3,030,000. Finally, Ghisallo Capital Management LLC purchased a new stake in shares of Lucid Diagnostics in the third quarter worth approximately $2,990,000. 74.01% of the stock is owned by institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.